Yüklüyor......
Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer
BACKGROUND: Programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) blockade therapy fails in the majority of patients with cancer. Oncolytic viruses represent a new class of therapeutic agents, yet the therapeutic efficacy is still disappointing. Moreover, intratumoral injection of viruses...
Kaydedildi:
| Yayımlandı: | J Immunother Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMJ Publishing Group
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7254155/ https://ncbi.nlm.nih.gov/pubmed/32461344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000294 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|